Stem cells: how effective are they and how is response measured?
Stem cells work differently depending on the indication and the patient. Here we explain what the evidence says and how clinical response is measured.

Stem cells. Realistic expectations.
When someone asks us whether stem cells work, the honest answer does not fit into a yes or a no. It fits into a question in return: for which indication, at what stage in the condition's progression, and with what measurable objectives? That is not evasion; it is the exact framework medicine uses to evaluate any intervention. And with cell-based therapies, that framework matters more than in almost any other field.
What follows is a review of what the current evidence supports, what remains under investigation, and what, as of today, lacks sufficient backing to be recommended outside a rigorous clinical protocol. No fabricated percentages. No recovery narratives. Only the categories we use when making clinical decisions.
What it means for stem cells to be effective: the distinction that matters
Saying that stem cells are effective without adding an indication is like saying an antibiotic works without specifying which bacterium. Efficacy is defined by contrast: against which condition, measured by which criterion, within which time window. Without that framework, the statement has no clinical content.
Regenerative medicine distinguishes three categories of backing: what is approved, what is in active clinical investigation, and what lacks sufficient evidence. These categories are not permanent; research advances, and what is under study today may hold a different status in years to come. But operating as though everything belongs in the first category is a mistake paid for with broken expectations.
What is approved with solid regulatory backing includes hematopoietic stem cell transplantation in blood diseases and certain oncological conditions. Beyond that, most of the applications that generate the most interest, such as the management of joint conditions, neurodegenerative diseases, or aging processes, are at various phases of clinical investigation. Some with results that justify continued study; others with weaker signals.
Efficacy is not a property of stem cells in the abstract. It is a relationship between a cell, a specific indication, and a particular patient with their own biology.
What definitively does not apply today is using cellular therapies as a resource for any condition that lacks an active research protocol and genuine medical supervision. Application without clinical criteria is not regenerative medicine: it is something else entirely.
How we assess whether stem cells work in a given patient
The clinical response to a cellular therapy is not measured with a single variable. It is built from multiple signals over time: changes in functional symptoms, findings from imaging or laboratory studies, and systematic comparison with the patient's baseline state ahead of the protocol.
In practice, the follow-up tools most commonly used in clinical research include:
- Functionality scales: changes in movement capacity, autonomy, or performance in specific activities that the patient reports and the physician verifies.
- Inflammatory and metabolic biomarkers: blood markers that may reflect changes in the physiological environment, though their interpretation requires clinical context.
- Imaging studies: in musculoskeletal indications, for example, MRI can document tissue changes over months.
- Pain and quality-of-life records: validated tools that convert the patient's subjective experience into comparable data.
None of these tools works in isolation. A change in a biomarker without a functional correlate is not enough. A self-reported improvement with no objective marker is not enough either. Real clinical response lives in the convergence of those signals, and that requires structured follow-up, not a single review.
Why response varies: individual biology and timing of indication
Two people with the same diagnosis can have different responses to an identical protocol. This is not a flaw in the treatment; it is biology. The age of the recipient tissue, baseline inflammatory burden, the presence of concurrent conditions, and the timing of the intervention within the disease's progression are variables the evidence identifies as relevant.
To understand what makes an indication more or less likely to respond, one must understand what the cells are expected to do in that tissue. In general terms, the mechanisms under investigation include modulation of the inflammatory environment, paracrine signaling (cells release molecules that affect their surroundings), and in some cases differentiation toward specific cell types. Each of those mechanisms has conditions that favor or hinder it.
The timing of an intervention within the natural history of a condition matters as much as the indication itself. Intervening at an advanced stage of structural damage carries a different potential than intervening at an early stage.
That is why, in the assessment of a cell therapy clinic in Mexico, one of the most important criteria is precisely whether the team makes that distinction: whether they explain at which phase of your condition the therapy has backing, and at which phase it does not. If they do not, that says something about the clinical judgment with which they operate.
What remains under investigation and why that does not mean it does not work
An indication being "under investigation" does not mean it is useless, nor that it is experimental in the colloquial sense of the word. It means the evidence does not yet have the volume and consistency required for formal regulatory backing, but that there are sufficient signals for serious clinical teams to dedicate resources to studying it with rigorous protocols.
Some of the areas with active research in cellular therapies include degenerative joint conditions, certain neurological conditions, autoimmune conditions, and protocols oriented toward aging biomarkers. In all of those areas, the question is not "does it work or not?", but rather "does it work in which patients, with which protocol, measured by which criteria?" That is the question research teams are answering now.
At Longevia Medical, the regenerative area is supervised by Dr. María Guadalupe Navarro Barrientos, Physician and Homeopath (IPN), with a Master's degree in Molecular Biomedicine (IPN) and a Doctorate in Medical Research from the Escuela Superior de Medicina del IPN. Her line of work includes hyperbaric oxygenation and oxidative biomarkers. That training matters because it distinguishes someone who investigates from someone who only applies.
Regarding the evidence-backed indications in stem cells and their limits, our position is the same as that of any team with clinical judgment: what is approved is stated clearly; what is under study is described as such; what lacks backing is not offered.
Stem cells are effective: when that statement actually holds
There are contexts in which it is reasonable to say that stem cells are effective. Hematopoietic transplantation in certain leukemias and lymphomas has decades of evidence and is part of the standard of care in oncohematology. That is the firmest ground. In other indications, efficacy is more conditional: it depends on the exact indication, the stage of the condition, and how the follow-up protocol was designed.
What is never reasonable is presenting stem cells as a universal solution for any chronic condition. Not because regenerative medicine lacks potential, but because that potential is activated under specific conditions, and promising it to someone who does not meet those conditions is not therapy: it is something else entirely.
Candidacy for a protocol is determined in an individual assessment. If someone arrives with a condition that has research backing, that is explained clearly, with the current limits of the evidence and the variables that may modulate response. If it does not apply, that is stated as well. That honesty is not a shortcoming of the service; it is the foundation of clinical judgment.
How follow-up is built after a protocol
A cellular therapy without structured follow-up produces no useful clinical data. It produces subjective experiences that cannot be interpreted or improved upon. That is why, in any serious protocol, follow-up is not optional: it is the part that converts the intervention into information.
Follow-up includes scheduled reviews, repetition of the baseline studies used to establish the starting point, and adjustment of the plan if the response is not what was expected. This applies whether the patient is still in the city where they received treatment or has returned home. Distance does not suspend clinical responsibility.
At Longevia Medical, located in Puerto Cancún, care begins with an assessment, which can be in-person or remote. The plan is delivered in writing, is individual, and has medical supervision. Follow-up continues when the patient returns to their place of residence. That is not an elevated-tier protocol: it is the minimum standard a serious therapy requires.
A protocol without follow-up is an intervention without closure. What is not measured cannot be improved, and what cannot be improved should not be called medicine.
flowchart TD
A["Initial assessment: in-person or remote"] --> B["Determination of clinical candidacy"]
B --> C{"Does the patient have a supported indication?"}
C -->|"Yes"| D["Individual protocol design, delivered in writing"]
C -->|"No or under study"| E["State of the evidence is explained"]
D --> F["Application with medical supervision"]
F --> G["Follow-up: biomarkers and functionality"]
G --> H["Plan adjusted according to response"]
E --> I["Assessment of other options or future follow-up"]
Frequently asked questions about stem cells
Do stem cells work for degenerative joint conditions?
This indication is under active investigation. There are signals that justify continued study, but formal regulatory backing has not been consolidated. Candidacy is determined in an individual assessment that considers the stage of the condition and the patient's objectives.
How long does it take to see results from a stem cell protocol?
Response varies by indication and by each patient's individual biology. There is no universal timeline. Structured follow-up, with biomarkers and functional measurements, is the way to document whether there is a response and within what timeframe it manifests in that specific case.
Are stem cells effective for neurological conditions?
Some neurological conditions have active research involving cellular therapies, but none has reached the level of approval held by hematopoietic transplantation. What is under study is described as such: with its preliminary signals and with the limits the current evidence establishes.
How is it determined whether stem cells worked in a specific patient?
Blood biomarkers, validated functionality scales, imaging studies where applicable, and quality-of-life records are used. Real clinical response comes from comparing those measurements with the patient's baseline state, established ahead of the protocol.
What distinguishes a stem cell application with clinical criteria from one without?
An application with criteria explains which indication has backing, at which stage it applies, what will be measured and how often. It includes an initial assessment, a written plan, and structured follow-up. If any of those elements is missing, the clinical criteria are incomplete.
Additional reading for patients
For those who want to review general clinical information about cellular therapies ahead of an assessment, two widely consulted resources are Mayo Clinic and MedlinePlus. Neither replaces an assessment with a clinical team, but both provide useful context for arriving at that conversation with better questions.
If you have new symptoms or sudden changes, such as difficulty breathing, chest pain, or neurological symptoms that appear abruptly, go to the emergency room immediately. That is not the moment to seek a scheduled consultation.
If you are in the stage of researching your options with clinical criteria, the next step is an individual assessment, in person in Puerto Cancún or remotely from wherever you are. That is where we determine whether there is an indication, what the evidence says for your specific case, and how follow-up would be structured. What cannot be done ahead of that assessment is promise a response.
Begin privately
Tell us what you want to protect.
This first conversation is for orientation, not diagnosis. A coordinator will identify the right clinical pathway and explain the secure next step.
Request a private consultation↗